true
FY
0001419554
0001419554
2022-01-01
2022-12-31
0001419554
BBLG:CommonStock0.001ParValuePerShareMember
2022-01-01
2022-12-31
0001419554
BBLG:WarrantsToPurchaseCommonStock0.001ParValuePerShareMember
2022-01-01
2022-12-31
0001419554
2022-06-30
0001419554
2023-03-28
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
xbrli:pure
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
10-K/A
(Amendment
No. 1)
☒ |
ANNUAL
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For
the fiscal year ended: December 31, 2022
☐ |
TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For
the transition period from _________ to _________
Commission
File Number: 001-40899
Bone
Biologics Corporation
(Exact
name of registrant as specified in its charter)
Delaware |
|
42-1743430 |
(State
or other jurisdiction of
incorporation
or formation) |
|
(I.R.S.
employer
identification
number) |
2
Burlington Woods Drive, Ste 100, Burlington, MA 01803
(Address
of principal executive offices and Zip Code)
(781)
552-4452
(Registrant’s
telephone number, including area code)
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
stock, $0.001 par value per share |
|
BBLG |
|
The
Nasdaq Capital Market |
|
|
|
|
|
Warrants
to Purchase Common stock, $0.001 par value per share |
|
BBLGW |
|
The
Nasdaq Capital Market |
Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒
Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒
Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Yes ☒ No ☐
Indicate
by check mark whether the Company is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company,
or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller
reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):
Large
accelerated filer |
☐ |
|
Accelerated
filer |
☐ |
|
|
|
|
|
Non-accelerated
filer |
☒ |
|
Smaller
reporting company |
☒ |
|
|
|
|
|
|
|
|
Emerging
growth company |
☐ |
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate
by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report. ☐
If
securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant
included in the filing reflect the correction of an error to previously issued financial statements. ☐
Indicate
by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation
received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐
Indicate
by check mark whether the Company is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
Approximate
aggregate market value of registrant’s common equity held by non-affiliates of the registrant at the close of business on June
30, 2022, was $4,403,460.
As
of March 28, 2023, there were 16,702,912 shares of common stock, par value $0.001, outstanding.
Audit
Firm ID |
|
Auditor
Name |
|
Auditor
Location |
PCAOB
ID: 572 |
|
Weinberg
& Company, P.A. |
|
Los
Angeles, California |
EXPLANATORY
NOTE
Bone
Biologics Corporation (the “Company,” “we,” “us,” or “our”) is filing this Amendment
No. 1 (the “Amendment”) to our Annual Report on Form 10-K for its fiscal year ended December 31, 2022 filed with the Securities
and Exchange Commission (the “SEC”) on March 30, 2023 (the “Annual Report”), for the sole purpose of including
exhibits that were unintentionally omitted from the Annual Report.
In
addition, as required by Rule 12b-15 under the Securities Exchange Act of 1934, as amended, currently dated certifications by the Company’s
principal executive officer and principal financial officer required in accordance with Rule 13a-14(a) or 15d-14(a) are being filed as
exhibits to this Amendment and the exhibit list included in Item 15 of Part IV of the Annual Report has been amended accordingly.
Except
as described above, no other changes have been made to the Annual Report. This Amendment does not reflect events occurring after the
date of the Annual Report nor does it modify or update the disclosures contained in the Annual Report that may be affected by subsequent
events. Accordingly, this Amendment should be read in conjunction with the Annual Report and our other filings made with the SEC subsequent
to the filing of the Annual Report.
Part
IV
Item
15. Exhibits, Financial Statement Schedules
(3)
Exhibits. The following is a list of exhibits filed as part of this Annual Report on Form 10-K.
EXHIBIT
INDEX
Exhibit
No. |
|
Description |
|
|
|
2.1 |
|
Agreement and Plan of Merger, dated as of September 19, 2014, by and among AFH Acquisition X, Inc., Bone Biologics Acquisition Corp., and Bone Biologics, Inc. (incorporated herein by reference to Exhibit 2.1 to current report on Form 8-K, File No. 000-53078, filed September 25, 2014) |
|
|
|
2.2 |
|
Certificate of Merger as filed with the California Secretary of State effective September 19, 2014 (incorporated herein by reference to Exhibit 2.2 to current report on Form 8-K, File No. 000-53078, filed September 25, 2014) |
|
|
|
3.1 |
|
Amended and Restated Articles of Incorporation, of Bone Biologics Corporation, as filed with the Delaware Secretary of State on July 28, 2014 (incorporated herein by reference to Exhibit 3.1(i) to current report on Form 8-K, File No. 000-53078, filed September 25, 2014) |
|
|
|
3.2 |
|
Certificate of Amendment as filed with the Delaware Secretary of State on October 18, 2021 (incorporated herein by reference to Exhibit 3.1 to current report on Form 8-K, File No. 000-53078, filed October 15, 2021) |
|
|
|
3.3 |
|
Amended and Restated Bylaws of Bone Biologics Corporation (incorporated herein by reference to Exhibit 3.1 to current report on Form 8-K, File No. 000-53078, filed March 8, 2022) |
|
|
|
4.1 |
|
Warrant Agent Agreement including Form of Warrant between the Company and Equiniti (incorporated by reference to Exhibit 10.42 to current report on Form S-1, File No. 333-257484, filed October 7, 2021) |
|
|
|
4.2 |
|
Warrant Agent Agreement including Form of Series A Warrant, Form of Series B Warrant and Form of Series C Warrant between the Company and Equiniti (incorporated by reference to Exhibit 4.2 to current report on Form S-1, File No. 001-40899, filed September 23, 2022) |
|
|
|
4.3 |
|
Form of Representative’s Warrant (October 2021) (incorporated by reference to Exhibit A to Exhibit 1.1 to current report on Form 8-K filed October 15, 2021 |
|
|
|
4.4 |
|
Form of Representative’s Warrant (October 2022) (incorporated by reference to Exhibit A to Exhibit 1.1 to current report on Form 8-K filed October 15, 2021 |
|
|
|
4.5 |
|
Description of Securities* |
|
|
|
10.1 |
|
Director Offer Letter, dated July 1, 2014, by and between Bruce Stroever and Bone Biologics Corporation (incorporated herein by reference to Exhibit 10.4 to current report on Form 8-K, File No. 000-53078, filed September 25, 2014) |
|
|
|
10.2 |
|
Chief Operating Officer Employment agreement, dated June 8, 2015, by and between Bone Biologics Corporation and Jeffrey Frelick (incorporated herein by reference to Exhibit 10.2 to current report on Form 10-Q, File No. 000-53078, filed August 14, 2015) |
|
|
|
10.3 |
|
Letter Agreement, dated October 2, 2015, by and between the Company and the Founders (incorporated herein by reference to Exhibit 10.1 to current report on Form 8-K, File No. 000-53078, filed October 08, 2015) |
|
|
|
10.4 |
|
Bone Biologics Corporation Non-Employee Director Compensation Policy (incorporated herein by reference to Exhibit 10.1 to current report on Form 8-K, File No. 000-53078, filed January 4, 2016) |
|
|
|
10.5 |
|
Bone Biologics Corporation 2015 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.3 to current report on Form 8-K, File No. 000-53078, filed January 4, 2016) |
|
|
|
10.6 |
|
Form of Stock Award Grant Notice and Stock Award Agreement for the Bone Biologics Corporation 2015 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.4 to current report on Form 8-K, File No. 000-53078, filed January 4, 2016) |
|
|
|
10.7 |
|
Form of Restricted Stock Unit Award (incorporated herein by reference to Exhibit 10.5 to current report on Form 8-K, File No. 000-53078, filed January 4, 2016) |
|
|
|
10.8 |
|
Option Agreement for the Distribution and Supply of Sygnal™ dated as of February 24, 2016 (incorporated herein by reference to Exhibit 10.3 to current report on Form 8-K, File No. 000-53078, filed February 26, 2016) |
|
|
|
10.9 |
|
Form of Indemnification Agreement (incorporated herein by reference to Exhibit 10.17 to current report on Form 8-K, File No. 000-53078, filed September 25, 2014) |
10.10 |
|
Amended and Restated Exclusive License Agreement, dated as of March 21, 2019, by and between the Company and The Regents of the University of California (incorporated herein by reference to Exhibit 10.1 to current report on Form 8-K, File No. 000-53078, filed April 16, 2019) |
|
|
|
10.11 |
|
First Amendment to the Amended License Agreement dated August 13, 2020 between the Company and the Regents of the University of California (incorporated herein by reference to Exhibit 10.40 to current report on Form S-1/A, File No. 000-53078, filed October 7, 2021) |
|
|
|
10.12 |
|
Employment Agreement dated December 17, 2021 between the Company and Deina Walsh (incorporated herein by reference to Exhibit 10.1 to current report on Form 8-K, File No. 000-53078, filed December 22, 2021) |
|
|
|
10.13 |
|
Supply and Development Support Agreement dated March 3, 2022 between the Company and Musculoskeletal Transplant Foundation, Inc. (incorporated herein by reference to Exhibit 10.30 to annual report on Form 10-K, File No. 000-53078, filed March 15, 2022) |
|
|
|
10.14 |
|
Third Amendment to the Amended License Agreement dated June 8, 2022 between the Company and the Regents of the University of California (incorporated herein by reference to Exhibit 10.1 to current report on Form 8-K, File No. 001-40899, filed June 9, 2022) |
|
|
|
21.1 |
|
List of Subsidiaries (incorporated herein by reference to Exhibit 21.1 to current report on Form 8-K, File No. 000-53078, filed September 25, 2014) |
|
|
|
23.1 |
|
Consent of Weinberg & Company (incorporated herein by reference to Exhibit 23.1 to annual report on Form 10-K, filed March 30, 2023) |
|
|
|
24.1 |
|
Power of Attorney (incorporated herein by reference to signature page to annual report on Form 10-K, filed March 30, 2023) |
|
|
|
31.1 |
|
Certification of the Company’s Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, with respect to the registrant’s Report on Form 10-K/A for the year ended December 31, 2022.* |
|
|
|
31.2 |
|
Certification of the Company’s Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, with respect to the registrant’s Report on Form 10-K/A for the year ended December 31, 2022.* |
32.1 |
|
Certification of the Company’s Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (incorporated herein by reference to exhibit 32.1 to annual report on Form 10-K, filed March 30, 2023) |
|
|
|
32.2 |
|
Certification of the Company’s Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (incorporated herein by reference to exhibit 32.2 to annual report on Form 10-K, filed March 30, 2023) |
|
|
|
101.INS |
|
Inline
XBRL Instance Document (incorporated herein by reference to Exhibit 101.INS to annual report on Form 10-K, filed March 30, 2023) |
|
|
|
101.SCH |
|
Inline
XBRL Taxonomy Extension Schema Document (incorporated herein by reference to Exhibit 101.SCH to annual report on Form 10-K, filed
March 30, 2023) |
|
|
|
101.CAL |
|
Inline
XBRL Taxonomy Extension Calculation Linkbase Document (incorporated herein by reference to Exhibit 101.CAL to annual report on Form
10-K, filed March 30, 2023) |
|
|
|
101.DEF |
|
Inline
XBRL Taxonomy Extension Definition Linkbase Document (incorporated herein by reference to Exhibit 101.DEF to annual report on Form
10-K, filed March 30, 2023) |
|
|
|
101.LAB |
|
Inline
XBRL Taxonomy Extension Label Linkbase Document (incorporated herein by reference to Exhibit 101.LAB to annual report on Form 10-K,
filed March 30, 2023) |
|
|
|
101.PRE |
|
Inline
XBRL Taxonomy Extension Presentation Linkbase Document (incorporated herein by reference to Exhibit 101.PRE to annual report on Form
10-K, filed March 30, 2023) |
|
|
|
104 |
|
Cover
Page Interactive Data File * |
*
Filed Herewith
SIGNATURES
Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.
November
20, 2023 |
BONE
BIOLOGICS CORPORATION |
|
|
|
|
By: |
/s/
Jeffrey Frelick |
|
Name: |
Jeffrey
Frelick |
|
Title: |
Chief
Executive Officer (Principal Executive Officer) |
|
|
|
|
By: |
/s/
Deina H. Walsh |
|
Name: |
Deina
H. Walsh |
|
Title: |
Chief
Financial Officer (Principal Financial Officer and Principal Accounting Officer) |